Functional dyspepsia is predominantly attributed to gastric sensorimotor dysfunctions. The contribution of intestinal chemosensitivity to symptoms is not understood. We evaluated symptoms and plasma hormones during enteral nutrient infusion and the association with impaired glucose tolerance and quality-of-life (QOL) scores in patients with functional dyspepsia vs. healthy controls.
INTRODUCTION
A majority of patients with functional dyspepsia report postprandial symptoms (e.g., epigastric pain, fullness, early satiation, nausea, and vomiting), especially aft er meals rich in fat (1) (2) (3) . Th e pathogenesis of meal-related symptoms is incompletely understood. Most studies have focused on gastric sensorimotor dysfunctions. Although hypersensitivity to postprandial distention and impaired gastric accommodation are correlated with the severity of meal-related symptoms in several studies, abnormal (accelerated or delayed) gastric emptying typically is not ( 2 ) .
In the small intestine, the products of digestion stimulate release of enteral hormones (e.g., cholecystokinin (CCK)) that act through receptors on vagal aff erents to mediate postprandial sensations such as satiety ( 4 ) . Assessing proximal small intestinal nutrient sensitivity with orally administered nutrients is suboptimal because ingested nutrients stimulate the stomach and duodenum. Moreover, gastric emptying, and hence delivery of nutrients into the duodenum, may be normal, delayed, or rapid in functional dyspepsia ( 5 ) . Hence, enteral nutrient infusion is necessary to evaluate enteral nutrient sensitivity. Four small studies, of which one Normally, small intestinal delivery of nutrients evokes neurohumoral duodenogastric feedback mechanisms that inhibit gastric emptying by modulating gastric motor activity ( 4 ) . CCK, GLP1, and PYY induce satiety and delay gastric emptying by vagally mediated mechanisms. GLP1 and glucose-dependent insulinotropic peptide (GIP) also regulate glycemia.
Hence, the broad aims of this study were to compare sensitivity with duodenal nutrient infusion in functional dyspepsia and healthy individuals. We also evaluated the relation between nutrient sensitivity and day-to-day symptoms and, separately, plasma enteral hormone concentrations in functional dyspepsia and healthy individuals. Our hypotheses were that (i) patients with functional dyspepsia have more severe symptoms during enteral nutrient infusion, (ii) the severity of symptoms during enteral infusion is correlated with higher plasma levels of enteral hormones (e.g., CCK and GLP-1), and (iii) more severe daily symptoms and worse quality of life (QOL).
METHODS

Study participants
Th is study involved 35 healthy asymptomatic individuals (mean (s.e.) age, 41 (3) years; 24 women) with a mean (s.e.) body mass index (BMI) of 26.4 (0.7) kg/m 2 and 30 patients with functional upper GI symptoms (dyspepsia or nausea and vomiting) by Rome III criteria (mean (s.e.) age, 40 (3) years; 26 women) with a mean (s.e.) BMI of 26.4 (0.7) kg/m 2 ( Table 1 ). Recruitment of participants was made through public advertisement (controls) and from the clinical practice (patients). None of these participants was uncontrolled, suggest that duodenal lipid infusion increased the sensitivity to gastric distention in patients with functional dyspepsia (6) (7) (8) (9) . Th e sensitizing eff ect is blocked by a lipase inhibitor or a CCK-A receptor antagonist ( 10, 11 ) which suggests that CCK receptors mediate increased sensitivity to gastric distention during enteral lipid infusion.
However, several aspects are undetermined regarding duodenal chemosensitivity in functional dyspepsia. First, only two studies, with a total of 16 healthy subjects and 23 dyspepsia patients, evaluated duodenal nutrient sensitivity per se (i.e., without gastric distention). One of these studies only infused 5 kcal of dextrose and lipid in the duodenum. In these studies, duodenal sensitivity during intestinal nutrient infusion without gastric distention was not increased in functional dyspepsia ( 8, 12 ) . Second, in contrast to duodenal fat infusion, glucose infusion does not increase sensitivity to gastric distention in functional dyspepsia ( 6 ) , despite the observations that dextrose also evokes dyspeptic symptoms ( 1 ) . Th ird, the contribution of enteral hormones to symptoms in functional dyspepsia is unclear. Compared with healthy individuals, patients with functional dyspepsia had higher plasma concentrations of CCK aft er a high-fat meal ( 13 ) but not during enteral lipid infusion ( 8 ) . Other enteral hormones (e.g., glucagon-like peptide 1 (GLP1) and peptide YY (PYY)) that also inhibit gastric emptying and aff ect gastrointestinal (GI) sensation have not been evaluated during enteral nutrient infusions in functional dyspepsia. Fourth, the relation between symptoms during enteral nutrient infusion and day-today symptoms evoked by orally ingested meals is unknown in patients with functional dyspepsia. had previously participated in intubation studies. Exclusion criteria for all participants were age <18 or >70 years; a structural disorder aff ecting the GI tract; diabetes mellitus; clinically signifi cant systemic (e.g., cardiovascular, respiratory, renal) disease that may interfere with study objectives or pose safety concerns, or both; GI surgery other than appendectomy, cholecystectomy, hysterectomy, tubal ligation, or inguinal hernia repair; medications likely to aff ect GI motility; or a hemoglobin level <12.9 g/ dl in men and <11.5 g/dl in women. As age and BMI aff ect nutrient-induced hormone (e.g., CCK, ghrelin) release ( 14 ) , the age, sex distribution, and BMI of patients and healthy controls were matched. All women of child-bearing potential had to have a negative pregnancy test within 48 h of study participation. Th e Mayo Clinic Institutional Review Board approved the study, and all participants signed informed consent.
Assessment of dyspepsia symptoms
Th e self-administered Nepean Dyspepsia Index questionnaire was used to assess symptom severity and QOL related to dyspepsia in the past 3 months ( 15, 16 ) . Responses were summarized with the mean symptom severity score, calculated by fi rst averaging the frequency, intensity, and degree of bothersomeness for each of 15 symptoms and subsequently averaging across all 15 symptoms. Th ereaft er, this score is subtracted from 13 to obtain a mean symptom severity score; hence, lower scores correspond to increased symptoms. QOL was averaged for 5 domains to obtain an overall QOL that was then subtracted from 100; lower scores refl ect poorer QOL. Th e Hospital Anxiety and Depression Scale (HADS) questionnaire was used to identify anxiety and depression ( 17 ) .
Gastric and small-bowel transit
Study procedures (i.e., enteral nutrient infusion and gastric emptying) were performed on 2 separate days that were 8 days apart on average. Gastric emptying of solids and liquids and smallbowel transit were simultaneously assessed with established scintigraphic techniques in 30 of 35 healthy individuals and all 30 patients ( 18 ) . In the fi rst 5 healthy individuals, we sought to ensure that enteral infusions were well tolerated; hence, transit was not evaluated. Th e meal (296 kcal; 32% protein, 35% fat, and 33% carbohydrate) consisted of 2 eggs labeled with technetium Tc 99m sulfur colloid (1 mCi) served on 1 slice of bread with milk (240 ml; 1%) labeled with indium In 111 diethylenetriaminepentaacetate (0.1 mCi). Anterior and posterior gamma camera images were obtained immediately aft er ingestion of the radiolabeled meal, every 15 min for the fi rst 2 h, every 30 min for the next hour, and at 6 h. Gastric emptying and small-bowel transit were analyzed by quantifying counts in the stomach and colon, respectively, corrected as necessary for isotope decay, tissue attenuation, and downscatter of In 111 counts in the Tc 99m window. In patients, both rapid and delayed gastric emptying were defi ned relative to 10th through 90th percentile values in controls from this study. Rapid gastric emptying was defi ned as emptying >90th percentile value at 30 or 60 min or at half-time (t 50 ) less the 10th percentile value. Delayed gastric emptying was defi ned as emptying <10th percentile value at 2 or 4 h or t 50 longer than the 90th percentile value. Rapid gastric emptying of liquids was defi ned as emptying >90th percentile value in controls at 15, 30, or 60 min. Small-bowel transit time was calculated as the time for 10% of the activity to arrive at the cecum, aft er correcting for gastric emptying ( 19 ) .
Enteral nutrient infusions
On the enteral nutrient infusion day, an 8-Fr nasoduodenal feeding tube (Abbott Nutrition, Columbus, OH) was placed under fl uoroscopic guidance, with its tip in the second part of the duodenum. Th ereaft er, hormonal responses to dextrose and lipids were assessed, in randomized order, because nutrient composition infl uences hormonal release-for example, lipids and carbohydrates are more potent stimuli for CCK and GIP, respectively ( 20 ) -and we sought to characterize oral glucose tolerance. Th us, isocaloric (300 kcal) and isovolumic (222 ml) dextrose (Limeondex; Th ermo Fisher Scientifi c, Waltham, MA) (75 g) and lipid infusions (Microlipid; Covidien AG, Mansfi eld, MA) (66.7 ml diluted to 222 ml, for 0.5 g/ml) were administered in randomized order over 120 min, separated by a 120-mine washout period ( Figure 1 ) . Th e 75-g dextrose load was similar to an oral glucose tolerance test. As previously described ( 21 ) , the enteral glucose dosing regimen was designed to mimic the normal rate of systemic delivery of glucose aft er glucose ingestion (22) (23) (24) .
Symptoms during enteral nutrient infusion
During enteral nutrient infusion, participants reported the severity of 6 symptoms-nausea, fullness, bloating, abdominal pain, belching, and burning-at 15-min intervals on a Likert scale with 0 to 4 descriptors (absent, 0; light, 1; moderate, 2; severe, 3; and intolerable, 4). Th e proportion of participants with any symptom of moderate severity or worse was used for data analysis. were assessed during enteral dextrose and lipid infusions that were each administered over 2 h in randomized order. The variable caloric infusion rate was designed to mimic systemic delivery of glucose after oral ingestion of glucose.
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Glycemia and enteral hormonal measurements
Blood samples for measurement of plasma glucose, C-peptide, glucagon, GLP1, CCK, GIP, ghrelin, and PYY were collected at 5-min intervals for 30 min, at 10-min intervals from 30 to 60 min, and at 15-min intervals from 60 to 120 min. Arterialized venous plasma samples were obtained from a retrograde hand or forearm vein and were placed in a Perspex hot box heated to 55 °C. Samples were placed on ice, centrifuged at 4 °C, separated, and stored at −20 °C until assayed. Glucose was measured by the Hitachi 912 assay (Roche Diagnostics, Indianapolis, IN).
• GLP1 enzyme-linked immunosorbent assay (Linco Research) measures biologically active GLP1 (7-36, 7-37) amide levels with no crossreactivity to GLP1 (9-36) amide, GLP2, or glucagon; the threshold of detection is 3 pM. Immediately aft er collection, a dipeptidyl peptidase-4 inhibitor was added to these tubes.
• CCK immunoassay (Alpco Diagnostics, Salem, NH) uses rabbit antiserum to a synthetic cholecystokinin 26-33 sulfate (CCK 8 sulfate), binds to most biological active forms with nearly equimolar potency ( 25 ) , and has no crossreactivity with gastrin. To prevent degradation, the tubes contain aprotinin.
• GIP is measured with an enzyme-linked immunosorbent assay (Linco Research, EMD Millipore, Billerica, MA) that uses a monoclonal capture antibody with a 100% crossreactivity to intact human GIP(1-42) and human GIP(3-42) and has no measureable crossreactivity with glucagon, oxyntomodulin, GLP1, or GLP2.
• Th e PYY radioimmunoassay (Linco Research) detects 2 molecular physiologically active forms (1-36 and 3-36) and has no measureable crossreactivity with glucagon, ghrelin, insulin, or GLP1.
• Glucagon was measured with a direct, double-antibody radioimmunoassay (Linco Research) with no measurable crossreactivity to insulin, proinsulin, C-peptide, GLP1, or somatostatin.
• C-peptide levels are measured with a two-site immunometric (sandwich) assay using electrochemiluminescence detection (Cobas e411; Roche Diagnostics).
• Total ghrelin is measured with radioimmunoassay (Linco Research) that has no measurable crossreactivity with glucagon, GLP1 (7-36), or insulin.
Statistical analysis
Th e associations between symptoms during nutrient infusion and participant status (controls vs. patients) and separately with plasma hormone concentrations (i.e., mean levels) was evaluated by Fisher's exact test or Wilcoxon rank-sum test. Th e association between symptoms during enteral dextrose vs. lipid infusion was assessed by McNemar's test for paired data. Th e Wilcoxon rank sum test was used to assess the associations between symptoms during enteral infusion separately with mean plasma hormone concentrations, daily symptoms, and QOL assessed with the Nepean Dyspepsia Index. Associations between subject status (i.e., between patients with normal and impaired glucose tolerance) and plasma hormone concentrations were assessed with the Wilcoxon rank-sum test. Multiple linear regression models assessed whether anxiety, depression, and severe symptoms during either dextrose infusion or lipid infusion could predict mean symptom severity and QOL determined with the Nepean Dyspepsia Index instrument. Only 1 previous small study evaluated sensation during enteral nutrient infusion ( 8 ) . Hence, the sample size estimate was based on a study that evaluated CCK concentrations aft er comparable enteral lipid infusions ( 26 ) . Based on these observations, a sample size of 30 healthy participants vs. 30 patients provided ~80% power (two-sided α =0.05) to detect an association of subject status, with peak CCK values corresponding to a diff erence of 32% relative to the overall mean postprandial CCK concentrations.
RESULTS
Participants, study conduct, and completion
Th e GI transit was evaluated in 30 controls and 30 patients. Two controls and 5 patients did not receive either infusion because of inability to place a nasojejunal tube (1 control and 4 patients), positive pregnancy test (1 control), and concurrent illness (1 patient). Hence, 33 of 35 controls and 25 of 30 patients received at least one enteral infusion. Of these, 6 controls and 1 patient did not receive the second infusion because of adverse eff ects during the fi rst infusion. A total of 27 controls and 24 patients received both infusions.
Demographic and clinical characteristics
By study design, the sex distribution, BMI, and age were not signifi cantly diff erent between the control group and the patient group ( Table 1 ) . Th e predominant upper GI symptoms among patients were functional dyspepsia (i.e., postprandial distress alone ( n =17), epigastric pain alone ( n =2), and both ( n =8)), or functional nausea and vomiting ( n =3). Twenty patients also had bowel symptoms: constipation alone ( n =6), diarrhea alone ( n =9), or both ( n =4). A greater proportion of patients than controls had defi nite anxiety (i.e., HADS anxiety score >8; P =0.006) and depression ( P =0.052). In 23 patients, the upper GI endoscopy was essentially unremarkable (i.e., normal except perhaps for a small hiatal hernia or cystic fundic polyps). In the remaining patients, upper GI endoscopy disclosed antral erythema or minor erosions that were not deemed suffi cient to explain symptoms in fi ve patients, mild esophagitis (one patient), and retained food (one patient). No controls and four patients had a cholecystectomy.
Gastric emptying and small-bowel transit
On the basis of 10th to 90th percentile range for controls, the gastric emptying of solids and liquids was normal in 14 (47%) and rapid in 4 patients (13%). Th e other patients had rapid emptying of solids only ( n =6, 20%), rapid emptying of liquids only ( n =1, 3%), or delayed emptying of solids only ( n =5, 17%). Among patients with rapid gastric emptying of solids, mean (s.e.) gastric emptying from the stomach was 24% (3%) at 30 min, 39% (4%) at 60 min, and 75% (3%) at 120 min. At 30 min, this proportion was more than twice that in controls ( 
Glucose tolerance and plasma hormone concentrations during enteral nutrient infusion
Compared with controls, blood glucose concentration during dextrose infusion, as well as plasma GIP, GLP-1, and C-peptide concentrations during lipid infusion, were all higher ( P ≤0.03) in patients than controls ( Table 2 ) .
Indeed, the 90th percentile values for blood glucose concentration (area under the curve) during the 2-h dextrose infusion in 35 controls showed that 8 of 25 patients (32%) who completed the dextrose infusion had impaired glucose tolerance ( Table 3 ) . Age and BMI were not signifi cantly diff erent ( P≥ 0.6) in dyspeptic patients with normal (38±5 years, 26±1 kg/m 2 ) and impaired glucose tolerance (40±6 years, 27±2 kg/m 2 ). Plasma levels of GLP1 ( P =0.004) during dextrose infusion, and PYY ( P =0.01) during dextrose and lipid infusions, were higher in patients with impaired glucose tolerance than normal glucose tolerance ( Table 3 and Figure 3 ). In contrast, plasma concentrations of C-peptide, glucagon, and GIP, among other hormones, were not signifi cantly associated with glucose tolerance status ( Table 3 and Figure 4 ) .
Except for ghrelin, the plasma concentrations of all hormones increased during enteral nutrient infusions ( Figures 3 and 4 ) . Some plasma hormone levels (e.g., CCK) peaked early and stayed high for the duration of the infusion. Th e levels of others (e.g., GLP1, PYY) increased and also peaked later in the postprandial period. Among controls, the levels of plasma glucose, C-peptide, and GIP were higher ( P <0.001) during dextrose infusion than lipid infusion, but glucagon levels were higher ( P =0.02) during lipid infusion ( Table 2 ) .
With the exception of blood glucose concentration in controls, which was higher ( P =0.01) when the dextrose infusion was given aft er the lipid infusion, plasma hormone concentrations in controls and patients, as well as the blood glucose concentration in patients, were not signifi cantly associated with the order of dextrose vs. lipid infusion.
Relation between symptoms and plasma hormone concentrations during enteral nutrient infusion
During dextrose infusion, symptom status was associated with plasma glucagon ( P <0.05), glucose ( P= 0.06), and GLP1 ( P =0.09) (61±3% (controls) and 56±3% (patients)) and 60 min (78±3% (controls) and 72±3% (patients)) diff erences between controls and patients were not statistically signifi cant. Four patients had accelerated small-bowel transit.
GI symptoms during enteral nutrient infusion
More patients than controls reported at least 1 symptom of mode rate severity or worse during lipid (4 controls vs. 14 patients; P ≤0.01) and dextrose (1 control vs. 12 patients; P ≤0.01) infusions ( Figure 2 ). Patients who had moderate symptoms or worse during lipid infusion were also more likely ( P <0.001) to have symptoms during dextrose infusion. Th us, 11 of 18 participants (61%) who reported, but only 1 of 30 participants (3%) who did not report, moderate or more severe symptoms during lipid infusion also reported these symptoms during dextrose infusion.
Individual symptoms
Nausea was the most frequently reported severe symptom during dextrose and lipid infusions. A greater proportion of patients had moderate or more severe nausea ( P <0.001) and fullness ( P <0.02) during dextrose infusions and lipid infusions ( P <0.006 and P <0.05, respectively), as well as bloating ( P <0.01) during lipid infusions. Th e prevalence of moderate or more severe fullness ( P =0.025), bloating ( P =0.008), and abdominal pain ( P =0.06) was also higher during lipid infusion than dextrose infusion.
Timing of severe symptoms
Patients who reported moderate symptoms or worse generally reported them within 15 min (8 patients (dextrose) and 7 patients (lipid)) or 30 min (11 patients (dextrose) and 12 patients (lipid)) aft er infusions were started. Only 2 patients reported the onset of moderate or more severe symptoms at 45 and 60 min, respectively, aft er infusions were started. Th ese symptoms persisted thereaft er; the greatest proportion of participants who reported "signifi cant" symptoms occurred at 45 min into the infusion for controls and 75 min into the infusion for patients. Even at 120 min into the infusion, 12 patients reported symptoms during both infusions and 3 patients reported symptoms during lipid infusions only. 
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concentrations and was more severe in participants with, than without, moderate or more severe symptoms ( Table 4 ). Moreover, a higher proportion ( P =0.09) of participants with, than without, moderate or more severe symptoms had plasma GLP1 concentrations greater than the 90th percentile value in controls ( Figure 5 ). Seven of 17 patients (41%) with normal and 5 of 7 (71%) with impaired glucose tolerance had moderate or more severe symptoms during carbohydrate infusion; however, the diff erences were not signifi cant ( P= 0.37).
During lipid infusion, plasma GIP ( P <0.05) and GLP1 ( P <0.05) concentrations were associated with moderate or more severe symptoms, being greater in patients with, than without, these symptoms. Moreover, a higher proportion of participants with, than without, moderate or more severe symptoms had plasma CCK ( P =0.03) and GIP ( P =0.01) concentrations greater than the 90th percentile in controls ( Figure 5 ). Other hormones-PYY, ghrelin, glucagon, and C-peptide-were not associated with these symptoms during the infusions. 
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Relation between symptoms of dyspepsia and sensitivity during enteral nutrient infusion
Moderate or more severe symptoms during enteral dextrose or lipid infusion were associated with worse upper GI symptoms, as identifi ed by the Nepean Dyspepsia Index: abdominal pain ( P =0.01), postprandial distress ( P =0.001), and mean symptom score ( P =0.01). Moderate or more severe symptoms during infusions were also associated with worse QOL ( P =0.02).
Relation between GI transit and plasma hormone concentrations
In all, 2 of 6 patients (33%) with normal gastric emptying, 6 of 16 (38%) with rapid gastric emptying, and none of 3 (0%) with delayed gastric emptying had impaired glucose tolerance. Th e proportions were not diff erent among these gastric emptying groups. Plasma PYY concentrations were inversely correlated with small-bowel transit time during dextrose infusion ( r =−0.43; P =0.004) and lipid infusions ( r =−0.30; P <0.05). Other plasma hormone concentrations were not correlated with small-bowel transit time.
Relation among anxiety, depression, enteral nutrient sensitivity, and GI symptoms Mean (s.d.) depression scores were higher in patients with (4.2 (1.1)), than in patients without (2.2 (0.4)), moderate or more severe symptoms during dextrose infusion ( P =0.04). Otherwise, anxiety and depression scores were not signifi cantly associated with these symptoms during enteral infusions.
In the multiple linear regression models, the predictor variables (HADS anxiety and depression scores and moderate or more severe symptoms during dextrose or lipid infusion) explained 24% and 33% of the interparticipant variation in mean symptom severity and QOL, respectively. Moderate or more severe symptoms during either dextrose infusion or lipid infusion were the strongest Bharucha et al.
enteral infusion, at 6 kcal/min for 10 min ( 30 ) . Th e observed associations between moderate or more severe symptoms and greater plasma concentrations of hormones (i.e., CCK, GLP-1, GIP, and glucagon) during nutrient infusion are consistent with the eff ects of CCK and GLP1 that mediate satiation and nausea by stimulating receptors on vagal aff erents and centrally mediated eff ects ( 8, 31 ) . CCK release during intraduodenal fat infusion also relaxed the lower esophageal sphincter and increased gastroesophageal acid refl ux, and this may partly explain why symptoms of dyspepsia and refl ux occur concurrently ( 32 ) . Indeed, the CCK antagonist dexloxiglumide inhibited upper GI symptoms during duodenal lipid perfusion ( 8 ) . Neither physiological nor pharmacological concentrations of GIP regulate satiety in humans ( 33 ) . We were surprised to uncover impaired glucose tolerance in one-third of patients with functional dyspepsia. Diff erences in glycemic exposure between patients with normal glucose tolerance and impaired glucose tolerance were striking. Moreover, patients with impaired glucose tolerance also had higher plasma levels of GLP1 and PYY, refl ecting greater secretion, during dextrose and lipid infusions.
Marked hyperglycemia (blood glucose ~270 mg/dl) increases symptoms (e.g., nausea, fullness) during gastric distention even in healthy subjects ( 34 ) . One possible limitation is that hyperglycemia may contribute to symptoms in patients with dyspepsia and impaired glucose tolerance. Although a greater proportion (71% vs. 41%) of patients with impaired than normal glucose tolerance had moderate or more severe symptoms during carbohydrate infusion, the diff erences were not signifi cant. Moreover, hyperglycemia cannot be invoked to explain severe symptoms during lipid infusion. Out of eight patients with impaired glucose tolerance, six also had rapid gastric emptying that can cause hyperglycemia and exaggerated hormonal responses (e.g., GLP1, GIP, insulin) aft er nutrient ingestion (35) (36) (37) (38) . In this study, however, impaired glucose tolerance cannot be explained by rapid gastric emptying because the enteral nutrients were delivered at the same rate in all participants. Th e correlation between plasma PYY concentrations and small-bowel transit time is suggestive that rapid intestinal transit with increased delivery of nutrients to the lower small intestine might explain, at least partly, the exaggerated release of PYY.
Normally, GLP1 improves glucose tolerance by stimulating glucose-dependent insulin release and inhibiting glucagon secretion, among other mechanisms. In contrast, patients with impaired glucose tolerance had increased plasma glucose concentrations despite increased GLP1 release. Moreover, increased GLP1 release was not accompanied by increased plasma C-peptide or reduced plasma glucagon concentrations. Taken together, these fi ndings suggest reduced β -islet cell responsiveness or insulin sensitivity or both; however; they need to be confi rmed with mathematical modeling of glucose disposition and with additional prospective studies. Conceivably, interindividual diff erences in response to GLP1 may be explained by genetic variations that reduce the function of GLP1 receptors ( 39 ) . As GLP1 contributes to postprandial gastric accommodation ( 40, 41 ) , it is tempting to speculate that decreased predictor of the mean symptom score and explained 18% of the interparticipant variation. Th e HADS depression score explained 21% of the interparticipant variation in QOL.
DISCUSSION
Th e contribution of intestinal chemosensitivity and hormones to symptoms in functional dyspepsia is unclear. To avoid the confounding eff ect of delayed or accelerated gastric emptying, we evaluated intestinal chemosensitivity by directly infusing nutrients into the duodenum at the same controlled rate in controls and patients. Th ree important and original observations were made. First, patients with functional dyspepsia reported more severe symptoms during enteral lipid and dextrose infusions. Second, increased sensitivity was associated with greater plasma concentrations of enteral hormones during lipid infusion. Th ird, patients with increased sensitivity during enteral infusion also had more severe dyspeptic symptoms and reported a more pronounced impact of dyspepsia on QOL. Aft er adjustment for anxiety and depression, symptoms during either dextrose or lipid infusion were the strongest and only independent predictor of the mean symptom score and explained 18% of the interparticipant variation in symptom severity. Taken together, these fi ndings implicate a role for intestinal nutrient sensitivity to symptoms in functional dyspepsia. Fourth, nearly onethird of patients with dyspepsia with normal fasting glucose had impaired glucose tolerance during enteral nutrient infusion. Impaired glucose tolerance was associated with higher plasma concentrations of GLP1 during dextrose and PYY during dextrose and lipid infusions.
Duodenal infusion of lipids increases gastric accommodation and sensitivity to gastric distension (6) (7) (8) (9) 27 ) . In this study, patients with functional dyspepsia were more sensitive to duodenal lipid and dextrose infusions without gastric distention, suggestive of increased intestinal chemosensitivity. Although a relatively small volume (222 ml over 2 h) was infused, we cannot be certain whether symptoms during enteral nutrient infusion were related to distention per se or were due to chemosensitivity. However, duodenal infusion of saline (216 ml over 90 min) did not aff ect perception of gastric distention in humans ( 28 ) . Hence, diff erences between patient and control groups are unlikely to be explained through increased mechanosensitivity. Because we sought to mimic the pattern of glucose delivery into the circulation during an oral glucose tolerance test, the infusion rate over the fi rst 15 min in this study was at t he higher end of the rate in previous studies that evaluated the eff ects of duodenal lipid infusion (i.e., 4 kcal/min) ( 29 ) . Conceivably, the intestinal caloric delivery rate in the present study approximates that in patients with rapid gastric emptying.
During enteral infusion, CCK and GIP increased fi rst, followed by increase in GLP1 and, fi nally, increase in PYY. Th is pattern is consistent with the site of release of these hormones in the small intestine: duodenum for CCK and GIP, jejunum and ileum for GLP1, and ileum for PYY. Th e threefold increase in plasma GLP1 concentration is similar to the increase observed during
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Enteral Chemosensitivity in Functional Dyspepsia responsiveness to GLP1 might explain impaired gastric accommodation, which underlies functional dyspepsia, and impaired glucose tolerance. Moreover, patients had rapid gastric emptying despite increased plasma concentrations of GLP1 and PYY, suggestive that rapid gastric emptying cannot be explained by impaired secretion of these hormones that are mediators of the gastric brake. To the contrary, they suggest the possibility that the end-organ mechanisms in the stomach are resistant to these hormones.
Th e severity of symptoms aft er a meal is associated with postprandial sensitivity to balloon distention and, in some studies, with impaired gastric accommodation ( 2, 42, 43 ) . Selected symptoms (e.g., postprandial fullness, vomiting) recorded over a longer duration, typically a few weeks, were also associated with delayed gastric emptying in some studies of functional dyspepsia ( 5 ) . In this study, increased nutrient sensitivity was associated with not only increased severity of day-to-day symptoms, but also poorer QOL in functional dyspepsia, confi rming the criterion validity of these measurements. Moreover, in the multiple variable models, symptoms resulting from infusion of nutrients and depression were the only signifi cant predictors of overall symptom severity and QOL in functional dyspepsia, respectively. Taken together, these fi ndings are aligned with the biopsychosocial model of dyspepsia ( 44 ) and highlight the greater contribution of enteral nutrient sensitivity to symptom severity and of depression to QOL. Of particular interest, patients with functional dyspepsia had duodenal mucosal infl ammation, altered expression of mucosal tight junction proteins, and increased mucosal permeability ( 45 ) that might conceivably predispose to increased visceral sensitivity. Similarly, other studies have implicated a role for eosinophils in functional dyspepsia ( 46 ) . However, duodenal mucosal biopsies were not obtained in this study. Hence, we do not know whether these observations (e.g., increased enteral sensitivity to nutrient infusions) are associated with duodenal mucosal infl ammation. Although we cannot exclude tertiary care bias, the prevalence of anxiety and depression and dyspepsia symptom severity scores argue against the same. In summary, increased sensitivity to enteral dextrose and lipid infusions was associated with greater plasma concentrations of enteral hormone, more severe daily symptoms, and worse QOL in functional dyspepsia. Th ese observations are consistent with the hypothesis that enteral hormones mediate increased intestinal sensitivity to nutrients in functional dyspepsia.
